First Author | Shinohara M | Year | 2020 |
Journal | FASEB J | Volume | 34 |
Issue | 2 | Pages | 2425-2435 |
PubMed ID | 31907998 | Mgi Jnum | J:296508 |
Mgi Id | MGI:6467883 | Doi | 10.1096/fj.201901028RR |
Citation | Shinohara M, et al. (2020) Increased levels of Abeta42 decrease the lifespan of ob/ob mice with dysregulation of microglia and astrocytes. FASEB J 34(2):2425-2435 |
abstractText | Clinical studies have indicated that obesity and diabetes are associated with Alzheimer's disease (AD) and neurodegeneration. Although the mechanisms underlying these associations remain elusive, the bidirectional interactions between obesity/diabetes and Alzheimer's disease (AD) may be involved in them. Both obesity/diabetes and AD significantly reduce life expectancy. We generated App(NL-F/wt) knock-in; ob/ob mice by crossing App(NL-F/wt) knock-in mice and ob/ob mice to investigate whether amyloid-beta (Abeta) affects the lifespan of ob/ob mice. App(NL-F/wt) knock-in; ob/ob mice displayed the shortest lifespan compared to wild-type mice, App(NL-F/wt) knock-in mice, and ob/ob mice. Notably, the Abeta42 levels were increased at minimum levels before deposition in App(NL-F/wt) knock-in mice and App(NL-F/wt) knock-in; ob/ob mice at 18 months of age. No differences in the levels of several neuronal markers were observed between mice at this age. However, we observed increased levels of glial fibrillary acidic protein (GFAP), an astrocyte marker, in App(NL-F/wt) knock-in; ob/ob mice, while the levels of several microglial markers, including CD11b, TREM2, and DAP12, were decreased in both ob/ob mice and App(NL-F/wt) knock-in; ob/ob mice. The increase in GFAP levels was not observed in young App(NL-F/wt) knock-in; ob/ob mice. Thus, the increased Abeta42 levels may decrease the lifespan of ob/ob mice, which is associated with the dysregulation of microglia and astrocytes in an age-dependent manner. Based on these findings, the imbalance in these neuroinflammatory cells may provide a clue to the mechanisms by which the interaction between obesity/diabetes and early AD reduces life expectancy. |